ASX Announcement

Results of Annual General Meeting

24 November 2025 – Race Oncology Limited ("Race") advises that its Annual General Meeting of Shareholders was held today at 12.00 pm AEDT.

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange.

All resolutions were carried on a poll.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached to this announcement.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race's lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries have enabled composition of matter IP filings that may provide for 20 years of patent protection over RCDS1.

Race is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin where the aim is to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Race Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page at https://announcements.raceoncology.com

Release authorised by:

Board of Race Oncology
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au

Disclosure of Proxy Votes

Race Oncology Limited

Annual General Meeting

Monday, 24 November 2025

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 ADOPTION OF REMUNERATION REPORT	P	37,811,513	36,798,087 97.32%	188,274 0.50%	226,485	825,152 2.18%	45,972,556 99.59%	188,274 0.41%	226,485	-
2 ELECTION OF DIRECTOR – DR MEGAN BALDWIN	P	51,820,526	46,752,700 90.22%	3,496,559 6.75%	3,485,087	1,571,267 3.03%	54,555,712 92.36%	4,512,178 7.64%	4,587,040	Carried
3 RE-ELECTION OF DIRECTOR – DR PETER SMITH	P	55,097,613	54,239,739 98.44%	32,722 0.06%	208,000	825,152 1.50%	63,414,208 99.95%	32,722 0.05%	208,000	Carried
4 ISSUE OF INCENTIVE OPTIONS TO DR MEGAN BALDWIN	P	34,112,873	28,790,223 84.40%	3,721,383 10.91%	3,548,507	1,601,267 4.69%	35,075,791 88.57%	4,527,069 11.43%	4,650,460	Carried
5 ISSUE OF INCENTIVE OPTIONS TO DR SERGE SCROFANI	P	37,374,101	36,435,304 97.49%	83,645 0.22%	287,279	855,152 2.29%	43,882,396 99.81%	83,645 0.19%	287,279	Carried
6 ISSUE OF INCENTIVE OPTIONS TO DR PETER SMITH	P	37,419,571	36,512,274 97.58%	83,645 0.22%	241,809	823,652 2.20%	43,927,866 99.81%	83,645 0.19%	241,809	Carried
7 ISSUE OF OPTIONS IN LIEU OF BONUS ENTITLEMENTS – DR PETER SMITH	P	37,419,571	36,522,888 97.60%	73,031 0.20%	241,809	823,652 2.20%	43,938,480 99.83%	73,031 0.17%	241,809	Carried
8 ISSUE OF OPTIONS IN LIEU OF BONUS ENTITLEMENTS – DR DANIEL TILLETT	P	37,419,571	36,535,453 97.64%	60,466 0.16%	241,809	823,652 2.20%	43,833,895 99.86%	60,466 0.14%	358,959	Carried

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
9 REPLACEMENT OF CONSTITUTION	P	54,979,788	53,519,679 97.34%	525,708 0.96%	325,825	934,401 1.70%	62,432,680 99.16%	525,708 0.84%	696,542	Carried
10 CHANGE OF COMPANY NAME	P	52,353,857	49,932,710 95.38%	1,434,447 2.74%	2,951,756	986,700 1.88%	58,578,373 96.50%	2,124,801 3.50%	2,951,756	Carried